Episode 11: Fam-Trastuzumab Deruxtecan-nxki - The Backstory
Type: Individual•Format: On-demand
Upon completion of this activity, participants will be able to:
- Articulate the reasoning behind an FDA oncology drug approval.
- Identify the relevant sections of the drug USPI where information is located.
- Integrate this information into their clinical practice.
Review video content here.
Time to Complete Activity: 75
Get It
In this episode:
- Preeti Narayan, MD, Breast and Gynecologic Malignancies Team Lead, Division of Oncology 1, Office of Oncologic Diseases, U.S. Food and Drug Administration (FDA)
- Asma Dilawari, MD, Oncologist and Clinical Reviewer, Division of Oncology 1, Office of Oncologic Diseases, FDA
- Gerold Meinhardt, MD, PhD, Global Team Lead for fam-trastuzumab deruxtecan-nxki, Daiichi Sankyo, Inc.
- Naoto T. Ueno, MD, PhD, FACP, Director of University of Hawaii Cancer Center
- Kasey Hoggatt, Patient and Clinical Trial Participant
- Debora (Debbie) Geary, MS, BSN, RN, OCN, CCRP, Research Nurse Specialist Sylvester Comprehensive Cancer Center at University of Miami Health System
- Neha Mangini, PharmD, BCOP, Clinical Oncology Pharmacist, Breast Oncology, Huntsman Cancer Institute